^
    Back
    Association details:
    Biomarker:ALK TKD mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study

    Published date:
    11/20/2021
    Excerpt:
    Eight (six crizotinib-pretreated and two pretreated with crizotinib followed by alectinib) of the 21 ALKi-pretreated patients carried a point mutation of the ALK TKD, and had the biopsy collected between 1 and 14 days before ceritinib...all patients derived clinical benefit from ceritinib treatment.
    DOI:
    10.1016/j.lungcan.2021.11.007
    Trial ID:
    NCT01283516